Ross Haghighat Sells 7,088 Shares of Aduro Biotech Inc. (ADRO) Stock
Aduro Biotech Inc. (NASDAQ:ADRO) Director Ross Haghighat sold 7,088 shares of the company’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $15.50, for a total value of $109,864.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Aduro Biotech Inc. (NASDAQ:ADRO) opened at 13.85 on Friday. Aduro Biotech Inc. has a 1-year low of $7.26 and a 1-year high of $34.95. The stock’s 50 day moving average price is $12.43 and its 200 day moving average price is $12.87. The company’s market cap is $930.47 million.
Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.09. The business had revenue of $3.79 million for the quarter, compared to analyst estimates of $3.99 million. Aduro Biotech had a negative return on equity of 23.45% and a negative net margin of 72.04%. The business’s quarterly revenue was down 79.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.01 EPS. Equities research analysts forecast that Aduro Biotech Inc. will post ($1.34) earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company bought a new stake in Aduro Biotech during the third quarter worth about $321,000. United Services Automobile Association boosted its position in Aduro Biotech by 260.1% in the third quarter. United Services Automobile Association now owns 87,870 shares of the company’s stock worth $1,092,000 after buying an additional 63,470 shares during the last quarter. Zacks Investment Management boosted its position in Aduro Biotech by 43.9% in the third quarter. Zacks Investment Management now owns 16,801 shares of the company’s stock worth $209,000 after buying an additional 5,122 shares during the last quarter. Morgan Stanley boosted its position in Aduro Biotech by 258.3% in the third quarter. Morgan Stanley now owns 30,815 shares of the company’s stock worth $383,000 after buying an additional 22,215 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new position in Aduro Biotech during the third quarter worth approximately $514,000. 29.41% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on the company. Roth Capital reaffirmed a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Aduro Biotech in a research report on Thursday, October 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 target price on shares of Aduro Biotech in a research report on Friday, August 5th. Leerink Swann set a $14.00 price target on Aduro Biotech and gave the company a “buy” rating in a research report on Monday, October 24th. Finally, FBR & Co reissued an “outperform” rating and set a $20.00 price target (down from $22.00) on shares of Aduro Biotech in a research report on Wednesday, October 26th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Aduro Biotech currently has an average rating of “Hold” and a consensus target price of $21.33.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.